gilead sciences inc
(GILD:Consolidated Issue Listed on NASDAQ Global Select )
Andrew Cheng M.D., Ph.D.
Executive Vice President of HIV Therapeutics and Development Operations, Gilead Sciences Inc.
|Age||Total Calculated Compensation||This person is connected to 25 board members in 1 different organizations across 1 different industries.|
See Board Relationships
Dr. Andrew Cheng, MD, PhD has been an Executive Vice President of HIV Therapeutics and Development Operations at Gilead Sciences Inc. since January 28, 2015. Dr. Cheng served as Senior Vice President of HIV Therapeutics at Gilead Sciences, Inc. until January 28, 2015. Dr. Cheng has been Senior Vice President of Development Operations at Gilead Sciences Inc., since January 2009. Dr. Cheng is responsible for Gilead's biometrics, clinical operations, drug safety and public ...
333 Lakeside DrivePhone: 650-574-3000
Foster City, California 94404
Board Members Memberships*
Johns Hopkins University
University of California-Los Angeles
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Robert A. Bradway||Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Equity Award Committee|
|Andrew Philip Witty||Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee|
|Kenneth C. Frazier||Chairman, Chief Executive Officer and President|
Merck & Co. Inc.
|Olivier Brandicourt||Chief Executive Officer and Director|
|Richard A. Gonzalez||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|$1.6M||Compensation as of Fiscal Year 2014.|